A Safer and More Efficacious Cell Therapy Construct for Solid Tumors
Time: 11:30 am
day: Conference Day Two
Details:
- Showcasing a head-to-head comparison “ARTEMIS vs CAR Technology” in T-cell therapy against solid tumors
- Targeting Glypican 3 (GPC3) in advanced hepatocellular carcinoma (HCC)
- Designing ARTEMIS Antibody TCR (AbTCR) T-cells to overcome major hurdles in treating solid tumors
- Infiltrating solid tumors in an immunosuppressive microenvironment
- Demonstrating superior safety and efficacy of ARTEMIS T cells
